SepSight Diagnostics was incorporated in February 2019 by Ploughshare Innovations to commercialise a Protein biomarker assay for the early detection of sepsis. They now need to appoint a CEO designate to complete the information memorandum and raise seed funds for assay and prototype design activities. This initial phase of development will take the technology up to the pre-clinical validation inflection point.
The role requires an individual of the highest calibre who has significant business and strategic leadership experience within the medical device and diagnostics industry, ideally as CEO, and is passionate about improving healthcare and growing talent. The CEO designate will complement the technical team and external advisors and specifically be responsible for managing the commercial development, financial and corporate governance aspects of the proposed spin-out company, alongside ensuring that required funding is secured, with potential to be appointed as CEO if and when appropriate funding for the spin-out is secured. The candidate should clearly appreciate the various stage-gates and fund-raising cycles needed to develop a company with high-growth global potential. The ideal candidate is someone who has a demonstrated track record of success in managing a business with high-growth global potential, preferably in a start-up regulated medical environment.
The role will be remunerated on a day rate initially moving to a salaried position post fundraise as it moves to full time (4 or 5 days a week).